Medicare Advantage Newsfeed

Medicare Advantage plans submitted their 2027 benefit bids to CMS in early June 2026. Preliminary analysis from Oliver Wyman and Faegre Drinker Consulting suggests the market will stabilize relative to 2025–2026, when plans made aggressive benefit cuts, network reductions, and portfolio exits due to medical cost pressures. CMS announced an average revenue increase of 2.48% for 2027 vs. an initial estimate of 0.09%, providing relief. Regional plan exits are expected but at lower rates than 2026.

This signals improving MLR trajectories for Tier 1 and Tier 2 payers in 2027, reducing need for benefit degradation or aggressive cost-containment strategies. However, 'margin pressure amid modest increases' will persist, limiting benefit expansion. Implications: MA enrollment growth may reaccelerate modestly; supplemental benefits remain constrained; plan exits continue but are more surgical than reactive.

The Congressional Joint Economic Committee released analysis estimating that Medicare Advantage payers received approximately $7 billion in excess government payments annually, with the overpayment gap growing. This adds to mounting legislative scrutiny alongside the OIG prior auth/SNF denial findings.

This is high-profile legislative ammunition for MA rate adequacy cuts, risk adjustment audits, and potential payment system reforms. It raises political risk for Tier 1 payers' 2027–2028 profitability. Combined with prior auth denials and fraud cases (e.g., $56.5M settlement in early June), regulatory/legislative risk has shifted materially higher.

Humana announced the sale of its Gentiva hospice and end-of-life care business to a private equity buyer for approximately $900 million. This represents a strategic exit from the highly regulated post-acute care (PAC) services sector as Humana focuses on core MA and Medicare D operations.

This signals Humana's capital allocation priorities: divesting lower-margin, non-core PAC assets to fund MA/PBM growth and shareholder returns. It also reflects broader pressure on vertically integrated payer-provider models post-2024 medical cost inflation; pure-play MA operations are more profitable. Expect other payers to review similar divestitures (CVS may face similar pressure on Aetna's integrated assets).

Sagility, a healthcare technology and operations company, acquired CareSeed, an AI-powered platform for Medicare Advantage quality and risk operations. This is a tuck-in acquisition aimed at expanding Sagility's capabilities in MA quality metrics, star rating optimization, and care management.

Signals growing market appetite for AI-driven MA quality optimization tools as payers face margin pressure and star rating volatility (see Clover Health legal win). This is a positive signal for MA tech/services M&A and reflects payers' willingness to outsource quality operations to specialized vendors. Implications for MA payers: third-party quality vendors (Sagility, Milliman, etc.) will gain leverage in 2027.

A prior authorization reform bill became eligible for House fast-track (expedited) legislative consideration, signaling broad bipartisan momentum for reducing MA prior auth denials and burden. This comes directly after the OIG report on MA prior auth denial rates.

If this bill advances to law, it could mandate operational changes to MA prior auth processes, impose financial penalties, or require independent review of denials. This materially increases regulatory/legislative risk for all MA payers and could reduce their pricing power and enrollment growth in 2027–2028. Expect payers to lobby aggressively for narrow carve-outs.

Kaiser Family Foundation published analysis showing that Medicare Advantage plans' ability to use federal rebate dollars to subsidize Part D premiums and cost-sharing is creating severe competitive imbalance vs. stand-alone Part D drug plans (PDPs), contributing to instability and market consolidation in the PDP space.

This highlights a structural payment system inefficiency that favors large, integrated MA carriers (UNH, HUM, CVS, ELV) over pure-play Part D operators. It also signals emerging policy vulnerability: Congress may scrutinize MA rebate use, potentially leading to rate cuts or rebate restrictions. For MA payers, this is a watch item on Part D economics and cross-subsidy rules.

Fairview Health Systems announced it will not accept UnitedHealthcare Medicare Advantage beneficiaries in 2027, citing reimbursement and administrative issues. This is a significant in-network provider exit for UNH's MA book in the Upper Midwest.

This signals rising provider-payer friction over MA reimbursement rates and prior auth burden, particularly affecting Tier 1 payers with aggressive cost management. Similar exits may accelerate in 2027, creating network quality risk and beneficiary dissatisfaction. For UNH specifically, network erosion in key markets could pressure plan competitiveness and enrollments.